Skip to main content
. 2020 Jan 5;18:100238. doi: 10.1016/j.eclinm.2019.100238

Fig. 4.

Fig. 4

Estimated prevalence of HIV-1 drug resistance mutations in ART-naïve and ART-treated individuals with any SDRM. The major and minor resistance mutations are highlighted by dark and light violets, respectively. ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; FTC, emtricitabine; 3TC, lamivudine; TDF, tenofovir; DOR, doracirine; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine; ATV, atazanavir; IDV, indinavir; LPV/r, lopinavir/ritonavir; NFV, nelfinavir.